Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: Discontinuation and tolerability

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 463-471

  Noguera, Ana ^a,b,c,d   Ballesta, Patricia ^a,b,c,d   Baeza, Immaculada ^a,b,c,d   Arango, Celso ^d,e   De La Serna, Elena ^e   González Pinto, Ana ^d,f   Parellada, Mara ^d,e   Graell, Montserrat ^g   Moreno, Carmen ^d,e   Otero, Soraya ^d,h   Castro Fornieles, Josefina ^a,b,c,d  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^g HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

adolescents; antipsychotics; first psychotic episodes; treatment discontinuation

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BODY MASS; CHILD; CHILDHOOD DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT BEHAVIOR; AGE FACTORS; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHILD; CHILD BEHAVIOR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHOTIC DISORDERS; SPAIN; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84879839476     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182962480     Document Type: Article

References (33)

1. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18:418-428.
2. Castro-Fornieles J, Parellada M, Soutullo CA, et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol. 2008;18: 327-336.
3. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
4. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-145.
5. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21(8):621-645.
6. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appears in JAMA 2009;302(21):2322]. JAMA. 2009;302(16):1765-1773.
7. Frazier JA, Gordon CT, McKenna K, et al. An open trial of Clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:658-663.
8. Blanz B, Schmidt MH. Letter to editor, clozapine for schizophrenia. J Am Acad Child Adolesc Psychiatry. 1993;32:223-224.
9. Birmaher B, Baker R, Kapur S, et al. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Adolesc Psychiatry. 1992;31:160-164.
10. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63:524-529.
11. Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49:583-594.
12. Fraguas D, Merchán-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69:1166-1175.
13. Cianchetti C, Ledda MG. Effectiveness and safety of antipsychotics in early onset psychoses: a long-term comparison. Psychiatry Res. 2011;189(3):349-356.
14. Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006b;6:8.
15. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17:235-244.
16. Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67-77.
17. Ciudad A, Haro JM, Alonso J, et al. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry. 2008;23:1-7.
18. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050-1060.
19. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, et al. The Child and Adolescent First-Episode Psychosis Study (CAFEPS): design and baseline results. Schizophr Res. 2007;91(1-3):226-237.
20. Sánchez E, Carrascosa A, Fernández JM, et al. Estudios españoles de crecimiento: situación actual, utilidad y recomendaciones de uso. An Pediatr (Barc). 2011;74:193.
21. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age ChildrenYPresent and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
22. Peralta V, Cuesta M. Validación de la escala de los s?́ndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Esp Neurol Psychiatr. 1994;22:171-177.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education and Welfare; 1976.
24. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale. Arch Gen Psychiatry. 1976;33:766-777.
25. Hollingshead AB, Redlich FC. Social Class and Mental Illness. New York: Wiley; 1958.
26. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
27. Fraguas D, Llorente C, Rapado-Castro M, et al. Attitude toward antipsychotic medication as a predictor of antipsychotic treatment discontinuation in first-episode early-onset psychosis. Rv Psiquiatr Salud Ment. 2008;01:10-17.
28. Fleischhaker C, Heiser P, Hennighausen K, et al.Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm. 2008;115:1599-1608.
29. Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psych. 2007;46:1349-1356.
30. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting. Eur Neuropsychopharmacol. 2009;19(7): 520-532.
31. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165: 1432-1441.
32. McClellan J, McCurry C, Speltz, JL, et al. Symptom factors in early-onset psychotic disorders. J Am Acad Child Adolesc Psych. 2002;41:791-798.
33. Correll CU, Lencz T, Smith CW, et al. Prospective study of adolescents with subsyndromal psychosis: characteristics and outcome. J. Child Adolesc Psychopharmacol. 2005;15:418-433.